Abstract
Short bowel syndrome (SBS) comprises sequelaes of nutrient, fluid, and weight loss that occur subsequent to greatly reduced functional surface area of small intestine. Maintenance of fluid and electrolyte homeostasis in patients with SBS is often difficult; additional intravenous (i.v.) fluid and electrolytes are often required to cover unabsorbed secretory losses. The recent development of the synthetic long-acting release (LAR) depot octapeptide analog, octreotide, has rendered somatostatin therapy a practical alternative in patients with SBS who have become entrapped in a vicious cycle with chronic dehydration, thirst, and excessive fluid or food consumption.During an 8-month period, adult patients of either sex with SBS and total parental nutrition (TPN) dependent on III adaptation intestinal phase were included in a prospective, open-label study. We used single-subject research. Patients were divided into two groups: intestinal reinstated patients, group A (n = 6), and patients with high stomal output, group B (n = 4). Octreotide depot (20 mg intramuscularly [i.m.] at 0-8 months) was administered. Baseline and post-treatment measurements of nutritional status and stool losses were analyzed.Treatment with octreotide depot significantly reduced intestinal output (group A, p = 0.002, group B, p = 0.823), hospital stay, i.v. fluid and electrolyte requirements, in 80% TPN was not required.Octreotide depot is effective in diminishing i.v. fluid and electrolyte requirements by reducing stool losses in SBS patients. Multicenter studies with control group and larger sample size are required.
Highlights
Recognizing the important breakthroughs in the fight against vaccine-preventable diseases to protect the children of the Region made possible through the close partnership of the Member States
Considering the remarkable progress and experience gained by the Member States in the accelerated control
more rapid decrease of rubella cases and infants born with congenital rubella syndrome (CRS)
Summary
THE 44th DIRECTING COUNCIL, Having seen the progress report of the Director on sustaining immunization programs (Document CD44/11); Recognizing the important breakthroughs in the fight against vaccine-preventable diseases to protect the children of the Region made possible through the close partnership of the Member States and the international development community; Noting with great pride the sustained collective efforts by the Members States in fulfilling the goal of interruption of indigenous measles transmission in the Western Hemisphere; Considering the remarkable progress and experience gained by the Member States in the accelerated control of rubella and the prevention of congenital rubella syndrome (CRS) initiatives, which seek to achieve a more rapid decrease of rubella cases and infants born with CRS; Taking note of the spirit of solidarity and Pan Americanism in the implementation of the first Vaccination Week in the Americas that targeted immunization services to high-risk and underserved areas; Concerned with the fluctuations in the allocation of resources in public budgets to these activities at the national level, mainly due to economic downturns; and CD44.R1 (Eng.) Page 2.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
